Jeff Borgia, Ph.D. is the Director of the Rush Cancer Center Biorepository, where he oversees the collection and annotation of patient specimens in support of ongoing translational research projects ...

FREMONT, Calif., Feb. 24, 2025 /PRNewswire/ — Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the release of the ...

CD Bioparticles launches custom services and specialized kits designed for detecting cytokines with Homogeneous Luminescence Assay. NEW YORK, NY, UNITED STATES, June ...

In this free webinar, gain insight into method development and optimization of custom Laboratory Developed Test (LDT) assays, including critical steps identification and risk mitigation. Attendees ...

First in human (FIH) clinical trials of bispecific immunostimulatory antibodies commonly require a low starting dose based on a minimum anticipated biological effect level (MABEL) approach. To ...

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a series of enhancements for its QIAcuity series of digital PCR (dPCR) ...

SAN DIEGO--(BUSINESS WIRE)--Sapient, a leader in multi-omics discovery, has partnered with Alamar Biosciences, a pioneer in ultra-sensitive and highly multiplexed immunoassay technologies, to extend ...

Avance Biosciences opened its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and centralize the company’s capabilities in potency and functional ...

Precision medicine is driven by advances in omics technologies that facilitate identification of mutations and the presence or absence of certain molecular targets, which, in turn, enables streamlined ...